{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:05:55Z","timestamp":1791893155420,"version":"4.3.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eururo.2025.09.007","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:36:00Z","timestamp":1762259760000},"page":"31-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"given":"Irbaz Bin","family":"Riaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Arsalan","family":"Ahmed Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunwer Sufyan","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaneez Zahra","family":"Rubab Khakwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha H.","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelius","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Haruo","family":"Bryce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.09.007_b0005","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2021.39.6_suppl.11","article-title":"Final analysis results from TITAN: a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT)","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0015","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0020","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.007_b0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA5004","article-title":"Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC)","volume":"40","author":"Davis","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.007_b0040","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.007_b0045","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2x2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.007_b0050","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2022.40.6_suppl.136","article-title":"Triplet therapy in metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis","volume":"40","author":"Naqvi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0055","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5000","article-title":"Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): results of PEACE-1, a phase 3 randomized trial with a 2\u00a0\u00d7\u00a02 design","volume":"41","author":"Bossi","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0060","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.007_b0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2025.09.007_b0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.09.007_b0075","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0080","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.09.007_b0085","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0090","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","article-title":"The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic hormone-sensitive prostate cancer: a post hoc analysis of ARCHES","volume":"84","author":"Armstrong","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.007_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113290","article-title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study","volume":"193","author":"Merseburger","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.09.007_b0105","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.mcpdig.2024.05.023","article-title":"Future of evidence synthesis: automated, living, and interactive systematic reviews and meta-analyses","volume":"2","author":"Riaz","year":"2024","journal-title":"Mayo Clin Proc Digit Health"},{"key":"10.1016\/j.eururo.2025.09.007_b0115","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eururo.2025.09.007_b0120","doi-asserted-by":"crossref","first-page":"943","DOI":"10.18549\/PharmPract.2017.01.943","article-title":"Network meta-analysis: a technique to gather evidence from direct and indirect comparisons","volume":"15","author":"Tonin","year":"2017","journal-title":"Pharm Pract (Granada)"},{"key":"10.1016\/j.eururo.2025.09.007_b0125","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta\u2010analysis: model estimation using multivariate meta\u2010regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.eururo.2025.09.007_b0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2018.08.022","article-title":"GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks","volume":"105","author":"Brignardello-Petersen","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2025.09.007_b0135","unstructured":"Riaz IB, He H, Naqvi SAA, et al. A Living interactive systematic review and network meta-analysis on first-line treatment options in metastatic castration sensitive prostate cancer. https:\/\/mcspc.living-evidence.com\/."},{"key":"10.1016\/j.eururo.2025.09.007_b0140","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(23)00063-3","article-title":"Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Sweeney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0145","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \u201chigh-\u201d and \u201clow-risk\u201d metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.007_b0150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0155","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.007_b0160","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2025.09.007_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2022.11.010","volume":"14","author":"Francolini","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0170","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2017.75.3335","article-title":"Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer","volume":"36","author":"Morgans","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.21.00728","article-title":"Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial","volume":"40","author":"Rush","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0180","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/MOU.0000000000000985","article-title":"The role of chemotherapy in metastatic prostate cancer","volume":"32","author":"Riaz","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2025.09.007_b0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2025.09.007_b0190","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/jamaoncol.2023.1535","article-title":"Net clinical benefit as measure of treatment benefit among older adults with advanced incurable non\u2013small cell lung cancer","volume":"9","author":"Lee","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0195","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41585-020-0314-z","article-title":"The diverse roles of SPOP in prostate cancer and kidney cancer","volume":"17","author":"Wang","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.09.007_b0200","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","article-title":"SPOP mutations as a predictive biomarker for androgen receptor axis\u2013targeted therapy in de novo metastatic castration-sensitive prostate cancer","volume":"28","author":"Swami","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2025.09.007_b0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.007_b0210","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0215","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.eururo.2024.12.007","article-title":"Heterogeneity of the treatment effect with PARP inhibitors in metastatic castration-resistant prostate cancer: a living interactive systematic review and meta-analysis","volume":"87","author":"Naqvi","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.09.007_b0220","series-title":"Cochrane handbook for systematic reviews of interventions","first-page":"285","article-title":"Undertaking network meta\u2010analyses","author":"Chaimani","year":"2019"},{"key":"10.1016\/j.eururo.2025.09.007_b0225","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2022.40.6_suppl.089","article-title":"The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0230","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1200\/JCO.2022.40.16_suppl.5083","article-title":"Indirect comparisons of triplet therapy as compared to novel hormonal therapy doublets in patients with metastatic castration sensitive prostate cancer","volume":"40","author":"Naqvi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.09.007_b0235","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825005093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825005093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:41:03Z","timestamp":1773096063000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825005093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0302283825005093"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.007","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}